Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 7:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 989 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Diseases of the Musculoskeletal System and Connective Tissue Clear all

Conditions: Rheumatoid Arthritis
Interventions: CF101; Drug
Lead sponsor: Can-Fite BioPharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: Peoria, Arizona • Albany, New York • Cleveland, Ohio + 2 more

Conditions: Diabetes Mellitus, Foot Ulcer, Peripheral Neuropathy
Interventions: Achilles tendon-lengthening surgery; Procedure
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 0 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Rheumatoid Arthritis
Interventions: Placebo, M2951; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Billerica, Massachusetts

Conditions: Myositis, Dermatomyositis, Polymyositis, Juvenile Dermatomyositis
Interventions: Rituximab, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 5 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 27
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more

Conditions: Non-rhabdomyosarcoma Soft Tissue Sarcoma, Bone Sarcoma
Interventions: Proton Beam Radiation; Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Up to 30 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: PF-06438179, Infliximab; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 43
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 34 more

Conditions: Osteogenesis Imperfecta
Interventions: Invisalign; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 12 Years to 40 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • Bethesda, Maryland

Conditions: Dupuytren's Disease
Interventions: Clostridial collagenase injectable; Biological
Lead sponsor: Indiana Hand to Shoulder Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Indianaplis, Indiana • Stony Brook, New York

Conditions: Knee Osteoarthritis
Interventions: PEP/Euflexxa, PEP; Combination Product · Drug
Lead sponsor: Rion Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Rheumatoid Arthritis
Interventions: AIN457, Placebo; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 12
States / cities: Anniston, Alabama • Tucson, Arizona • Largo, Florida + 9 more

Conditions: Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer, Ovarian Sarcoma, Melanoma, Colon Cancer, Rectal Cancer, Breast Cancer, Eye Cancer, Uterine Sarcoma
Interventions: interleukin-2, MAGE-12 peptide vaccine, Montanide ISA-51; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Timeline: Started 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Osteoarthritis, Rheumatoid Arthritis, Other Inflammatory Arthritis, Post-Traumatic Arthritis, Juvenile Rheumatoid Arthritis, Avascular Necrosis
Interventions: Total Knee Arthroplasty, Total knee replacement; Device
Lead sponsor: DePuy Orthopaedics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 3
States / cities: Greensboro, North Carolina • Austin, Texas • Lakewood, Washington

Conditions: Juvenile Idiopathic Arthritis
Interventions: Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 11
States / cities: Little Rock, Arkansas • Hartford, Connecticut • Chicago, Illinois + 7 more

Conditions: Sjögren's Syndrome
Interventions: BMS-931699, BMS-986142, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 17
States / cities: Fullerton, California • Palo Alto, California • Sarasota, Florida + 14 more

Conditions: Rheumatoid Arthritis
Interventions: REGN88; Biological
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 24
States / cities: Santa Maria, California • Boca Raton, Florida • Clearwater, Florida + 21 more

Conditions: Rheumatic Diseases, Arthritis
Interventions: Not listed
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 7,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rheumatoid Arthritis
Interventions: SAIT101, MabThera, Rituxan; Biological
Lead sponsor: Archigen Biotech Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 15
States / cities: Anniston, Alabama • El Cajon, California • La Mesa, California + 10 more

Conditions: Sjögren, Sjogren Disease, Sjogren's Syndrome
Interventions: CLN-978; Drug
Lead sponsor: Cullinan Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Orlando, Florida • Brooklyn, New York • Memphis, Tennessee + 3 more

Conditions: Rheumatoid Arthritis
Interventions: CP-690,550 (tofacitinib), Methotrexate (MTX); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 4
States / cities: Daytona Beach, Florida • Fort Lauderdale, Florida • Miramar, Florida + 1 more

Conditions: Dermatomyositis
Interventions: Apremilast; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Lupus Erythematosus, Systemic
Interventions: Cenerimod; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 14
States / cities: Aurora, Colorado • Clearwater, Florida • DeBary, Florida + 8 more

Conditions: Systemic Juvenile Idiopathic Arthritis
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 19 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 15
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 10 more

Conditions: Dupuytren Contracture
Interventions: Pretendinous cord excision, Division/manipulation of the cord; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
Interventions: BMS-986165, Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients

Achilles Tendon Lengthening in Patients With Diabetes to Prevent Foot Ulcers

Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis

Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)

Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas

A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).

Clear Aligners for the Treatment of Dental Malocclusion in OI

Safety and Efficacy of Delayed Manipulation After Xiaflex Treatment in Subjects With Dupuytren's Contracture

Phase 1b Clinical Trial to Evaluate PEP and EUFLEXXA for Knee Osteoarthritis (KOA)

Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients

Vaccine Therapy in Treating Patients With Metastatic Cancer

Randomized Fixed Bearing vs Mobile Bearing Cruciate Substituting TKA

A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis

Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects

Studies of the Natural History of Rheumatic Diseases

PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

Co-Administration Of Methotrexate And CP-690,550

A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis

Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus

Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)

The Effects of Prophylactic Limited Palmar Fasciectomy on Surgical Outcomes and Scarring

The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients